Clinical trials: Heart Failure, Unspecified
Acute Heart Failure (AHF)
Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients
This was a multinational, multicenter, randomized, open-label study to confirm and expand the efficacy, safety and tolerability evidence of 48 hours intravenous infusion of serelaxin (30 micrograms/kg/day) when added to Standard…
- Trial name
- RELAX-AHF-EU (NCT02064868)
- Testing
- Serelaxin, Standard of Care
- Where
- 357 sites in Austria, Belgium and 23 more
- Volunteers
- 2,666 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Diabetes
Thiamine and Acute Decompensated Heart Failure: Pilot Study
Heart failure remains an increasing cause of morbidity and mortality in the United States even in the face of recent advances in the treatment of cardiovascular disease.
- Trial name
- NCT00680706
- Testing
- Thiamine
- Where
- 2 sites in United States
- Volunteers
- 131 people
- Sponsor
- Baystate Medical Center
Heart Failure With Preserved Ejection Fraction
Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
The purpose of this study was to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular death and heart failure(HF) hospitalizations in patients with HF with preserved ejection fraction.
- Trial name
- PARAGON-HF (NCT01920711)
- Testing
- LCZ696, Valsartan
- Where
- 715 sites in United States, Argentina and 41 more
- Volunteers
- 4,822 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Heart Failure
Acupuncture on Cardiac and Autonomic Function in Human Heart Failure
Acupuncture treatment may improve the cardiac function and the quality of life in heart failure patients. These effects may be related to the inhibition of sympathetic activity and/or increased vagal function.
- Trial name
- NCT01804816
- Testing
- Acupuncture, No Intervention
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- The Cleveland Clinic
Heart Failure
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)
Objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase III that can be given in addition to standard therapy for heart failure with reduced…
- Trial name
- NCT01951625
- Testing
- Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg)
- Where
- 157 sites in United States, Australia and 22 more
- Volunteers
- 456 people
- Sponsor
- Bayer
Type 2 Diabetes Mellitus, Heart Failure
Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure
This is a 24 week, multicenter, randomized, double-blind, parallel group, placebo-controlled study to investigate the effects of saxagliptin and sitagliptin on cardiac dimensions and function in patients with type 2 diabetes…
- Trial name
- MEASURE-HF (NCT02917031)
- Testing
- Saxagliptin, Sitagliptin
- Where
- 74 sites in United States, Bulgaria and 8 more
- Volunteers
- 348 people
- Sponsor
- AstraZeneca
Chronic Heart Failure, Atrial Fibrillation
The Influence of Heart Rate Limitation on Exercise Tolerance in Pacemaker Patients.
To examine the effects of heart rate reduction on exercise capacity in control subjects and patients with chronic heart failure.
- Conditions
- Chronic Heart Failure, Atrial Fibrillation, Arrhythmia, Sinus
- Trial name
- TREPPE (NCT02247245)
- Testing
- Ivabradine, Atrial fibrillation
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- University of Leeds
Cardiovascular Diseases, Atrial Fibrillation
A Digital Flu Intervention for People With Cardiovascular Conditions
A 6-month prospective, digital randomized controlled trial targeting approximately 49,000 individuals to evaluate the effectiveness of an influenza vaccination intervention during influenza season for people with cardiovascular…
- Conditions
- Cardiovascular Diseases, Atrial Fibrillation, Abnormal Heart Rhythms, Cardiac Arrest
- Trial name
- CardioFlu (NCT04584645)
- Testing
- Targeted digital intervention
- Where
- United States
- Volunteers
- 49,138 people
- Sponsor
- Evidation Health
Right Bundle-Branch Block, Heart Failure
Right Ventricular Septal Pacing in Patients With Right Bundle Branch Block and Heart Failure (The SPARK Trial)
This clinical study has been designed to test whether a new pacing therapy would lead to improvement in heart function, symptoms and quality of life in a specific group of heart failure patients.
- Trial name
- SPARK (NCT02441101)
- Testing
- RV DDD(R)-60 with AV optimization, RV DDD(R)-60
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Barry London
Type2 Diabetes, Heart Failure
Effect of Ertugliflozin on Cardiac Function in Diabetes
The aim of this study is to investigate the beneficial role of ertugliflozin, a new SGLT2 inhibitor, in cardiac function via measuring GLS as well as other hemodynamic factors using echocardiogram in patients with T2D and HF, who…
- Trial name
- ERTU-GLS (NCT03717194)
- Testing
- Ertugliflozin
- Where
- South Korea
- Volunteers
- 102 people
- Sponsor
- Soo Lim
Heart Failure，Congestive, Heart Failure New York Heart Association Class IV
Nicotinamide Riboside in LVAD Recipients
While preliminary data show that oral nicotinamide riboside (NR) supplementation increases myocardial levels of oxidized nicotine-adenine dinucleotide (NAD+) levels in mice, there has been no direct evidence that suggests oral NR…
- Conditions
- Heart Failure，Congestive, Heart Failure New York Heart Association Class IV, Mitochondrial Alteration
- Trial name
- PilotNR-LVAD (NCT03727646)
- Testing
- Nicotinamide riboside
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Washington
Heart Failure
Hemodynamically Guided Home Self-Therapy in Severe Heart Failure Patients (HOMEOSTASIS)
This study is a feasibility study of the HeartPOD™ Heart Failure Management System with DynamicRx® (HeartPOD system) in patients with severe chronic congestive heart failure.
- Trial name
- HOMEOSTASIS (NCT00547729)
- Testing
- HeartPOD™ System
- Where
- 7 sites in United States, Australia and 1 more
- Volunteers
- 71 people
- Sponsor
- Abbott Medical Devices
Pulmonary Arterial Hypertension
The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study
The purpose of this study is to find out if spironolactone added to ambrisentan for Pulmonary Arterial Hypertension (PAH) will increase exercise capacity.
- Trial name
- NCT02253394
- Testing
- Ambrisentan plus Spironolactone
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Brigham and Women's Hospital
Heart Failure With Preserved Ejection Fraction
Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%
This is a randomised, double-blind, placebo-controlled, multi-center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with…
- Trial name
- ENDEAVOR (NCT04986202)
- Testing
- AZD4831
- Where
- 171 sites in United States, Australia and 16 more
- Volunteers
- 711 people
- Sponsor
- AstraZeneca
Heart Failure, Diastolic Heart Failure
Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF
This study will be performed to determine the safety, tolerability, and dose-response to inorganic nitrate on exercise capacity in HFpEF. There are two primary goals for this study: 1.
- Trial name
- NCT02256345
- Testing
- KNO3, KCl
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Pennsylvania
Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation
The concept that direct stimulation of soluble guanylate cyclase (sGC) could be a particularly effective approach to increase cyclic guanosine monophosphate (cGMP) in conditions of increased inflammation/oxidative stress…
- Trial name
- NCT05420012
- Testing
- Vericiguat
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Josef Stehlik
Heart Failure
Spinal Stimulation During Exercise in Heart Failure
The purpose of this proposal is to determine whether epidural spinal cord stimulation can modulate cardiovascular control during exercise in Heart Failure patients.
- Trial name
- NCT02659202
- Testing
- Precision Spinal Cord Stimulator System
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Mayo Clinic
Heart Failure With Reduced Ejection Fraction
HF Patients With LVADs Being Treated With SGLT2i
The main purpose of this study is to observe outcomes of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in heart failure (HF) patients with left ventricular assist devices (LVAD).
- Trial name
- NCT05278962
- Testing
- SGLT2i, No SGLT2i
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Chicago
Heart Failure
A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin
The objective of this trial is to assess the effect of empagliflozin on cardiac physiology and metabolism aiming to provide a scientific explanation of the underlying mechanism by which empagliflozin improves HF related outcomes…
- Trial name
- NCT03332212
- Testing
- Empagliflozin
- Where
- United Kingdom
- Volunteers
- 72 people
- Sponsor
- Boehringer Ingelheim
Heart Failure
A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure
The purpose of this study is to determine the superiority of the effectiveness of canagliflozin 100 milligram (mg) daily versus placebo in participants with symptomatic heart failure (HF) in improving the overall Kansas City…
- Trial name
- CHIEF-HF (NCT04252287)
- Testing
- Canagliflozin 100 mg
- Where
- 18 sites in United States
- Volunteers
- 476 people
- Sponsor
- Janssen Research & Development, LLC